Burosumab for CSHS

Epidermal Nevus Syndrome Clinical Trial

Official title:

An Open Label Trial to Assess the Safety and Efficacy of Burosumab in a Single Patient With Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03993821
• Other study ID #: IRB 11746
• Status: Active, not recruiting
• Phase: Early Phase 1
• Start date: July 1, 2019
• Est. completion date: March 2023

Study information

• Verified date: March 2022
• Source: Children's National Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels. This drug is already approved for use in patients with X-linked hypophosphatemia (XLH), but not for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). It is hypothesized that burosumab may provide clinical benefit to a patient with CSHS due to the common underlying feature in this patient and in patients with XLH - abnormally elevated FGF23 in the context of low age -adjusted serum phosphorous levels.

Description:

There are multiple disorders (each with a unique underlying cause) that result in unusually high circulating levels of FGF23, which in turn result in renal phosphate wasting and reduced (or aberrantly normal in relationship to elevated FGF23) levels of 1,25-dihydroxy vitamin D (1,25[OH]2D). Across these disorders the clinical symptoms are similar and often include osteomalacia (and, in children, rickets), muscle weakness, fatigue, bone pain, and fractures. Burosumab has been FDA-approved for one of these disorders, X-linked hypophosphatemia (XLH). In single- and repeat-dose clinical studies in subjects with XLH, subcutaneous (SC) administration of burosumab consistently increased and sustained serum phosphorus levels and tubular reabsorption of phosphate (TRP) and improved radiologic rickets, without a major impact on urine calcium levels. Positive results were also observed in a nonclinical pharmacology model of XLH. It is hypothesized that burosumab may provide clinical benefit in this patient due to the common underlying feature in this patient and in patients with XLH - abnormally elevated FGF23 in the context of low age -adjusted serum phosphorous levels.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 1
• Est. completion date: March 2023
• Est. primary completion date: October 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

1. Patient has confirmed CSHS by physician diagnosis

2. Patient has confirmed FGF23 elevations in the context of a low fasting serum phosphorous < 2.5 mg/dL

3. Patient able to tolerate burosumab treatment

4. Have a corrected serum calcium level < 10.8 mg/dL

5. Have an eGFR >25 mL/min/1.73m2 (using CKD-EPI equation)

6. Must be willing in the opinion of the investigators, to comply with study procedures and schedule

7. Provide written informed consent by the subject or a Legal Authorized Representative (LAR) after the study has been explained and prior to any research related procedures begin

8. Must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study.

9. Must be willing to use a highly effective method of contraception for the duration of the study and for at least 12 weeks after the last dose of the study drug. Highly effective methods of contraception include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (e.g., oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (e.g., oral, injectable, implantable), intrauterine device (IUD) or intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, or sexual abstinence (i.e., refraining from heterosexual intercourse during the entire period of risk associated with the study treatments, when this is in line with the preferred and usual lifestyle of the subject) Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation

in this study:

1. Concomitant use of active vitamin D (i.e. calcitriol) and/or exogenous phosphate supplementation during burosumab therapy. Subjects will be allowed over the counter Vitamin D should levels drop below <20 ng/ml

2. Blood phosphorus level within or above the normal range while not taking phosphate or active Vitamin D.

3. Severe renal impairment or end-stage renal disease, defined as an eGFR of less than 25 ml/min/1.73m2

4. The use or enrollment in studies using other investigational therapies including other monoclonal antibodies

5. Subject or Legally Authorized Representative not willing or not able to give written informed consent

6. In the investigator's opinion, the subject may not be able to meet all the requirements for study participation

7. History of hypersensitivity to burosumab excipients that in the opinion of the investigator, places the subject at an increased risk of adverse effects

8. Subject has a condition that in the opinion of the investigator could present a concern for subject safety or data interpretation.

Related Conditions & MeSH terms

• Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
• Epidermal Nevus Syndrome
• Hypophosphatemia
• Syndrome

Intervention

Drug:
• Burosumab
Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.

Locations

Country	Name	City	State
United States	Children's National Hospital	Washington	District of Columbia

Sponsors (3)

Lead Sponsor	Collaborator
Laura Tosi	Children's National Research Institute, Ultragenyx Pharmaceutical Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum Phosphorus change	Change from baseline over 52 weeks in serum phosphorus with burosumab treatment.	52 weeks
Secondary	Changes in 1,25(OH)2-Vitamin D	Changes from baseline over 52 weeks in 1,25(OH)2-Vitamin D	52 weeks
Secondary	Changes in tubular reabsorption of phosphate (TRP)	Changes from baseline over 52 weeks in tubular reabsorption of phosphate (TRP)	52 weeks
Secondary	Changes in TmP/GFR (the ratio of renal tubular maximum phosphate reabsorption rate to glomerular filtration rate	Changes from baseline over 52 weeks in TmP/GFR (the ratio of renal tubular maximum phosphate reabsorption rate to glomerular filtration rate	52 weeks
Secondary	Biomechanical Marker	Effect of burosumab over 52 weeks on biochemical marker of bone turnover that reflects osteomalacia severity: alkaline phosphatase (ALP).	52 weeks
Secondary	6-minute walk test	Change in walking capacity over 52 weeks as assessed by 6-Minute Walk Test (6MWT)	52 weeks
Secondary	Sit-to-Stand test (STST)	Change in proximal muscle function over 52 weeks as assessed by the Sit-to-Stand test (STST)	2 weeks
Secondary	Brief Pain Inventory (BPI)	Change in Patient/parent-Reported Outcomes over 52 weeks as assessed by Brief Pain Inventory (BPI)	52 weeks
Secondary	Brief Fatigue Inventory (BFI)	Change in Patient/parent-Reported Outcomes over 52 weeks as assessed by Brief Fatigue Inventory (BFI)	52 weeks
Secondary	SF36 item short health survey (SF-36)	Change in Patient/parent-Reported Outcomes over 52 weeks as assessed by SF36 item short health survey (SF-36)	52 weeks
Secondary	PROMIS Pain Intensity	Change in Patient/parent-Reported Outcomes over 52 weeks as assessed by PROMIS Pain Intensity instrument. Pain is rated on a scale of 0-10 where 0 represents no pain and 10 represents the worst possible pain.	52 weeks
Secondary	PROMIS Pain Interference	Change in Patient/parent-Reported Outcomes over 52 weeks as assessed by PROMIS Pain Interference instrument. Responses are aggregated and converted to a T-score from 0-100 where 50 is the mean and every 10 is one standard deviation from the mean.	52 weeks
Secondary	PROMIS Physical Function with Mobility Aid	Change in Patient/parent-Reported Outcomes over 52 weeks as assessed by PROMIS Physical Function with Mobility Aid instrument. Responses are aggregated and converted to a T-score from 0-100 where 50 is the mean and every 10 is one standard deviation from the mean.	52 weeks
Secondary	PROMIS Fatigue	Change in Patient/parent-Reported Outcomes over 52 weeks as assessed by PROMIS Fatigue instrument. Responses are aggregated and converted to a T-score from 0-100 where 50 is the mean and every 10 is one standard deviation from the mean.	52 weeks